公开(公告)号：US20200024319A1

公开(公告)日：2020-01-23

申请号：US15565376

申请日：2016-05-04

Applicant: AMGEN INC. ,  Amgen Inc.

Inventor： Eric Alan BUTZ ,  Christy Ann THOMSON ,  Marc Alain GAVIN ,  Ian Nevin FOLTZ ,  Dong XIA ,  Dina N. ALCORN ,  Ai Ching LIM ,  Randal Robert KETCHUM ,  Kathy MANCHULENKO ,  Laura SEKIROV ,  Kelly Ann BERRY ,  Cyr Clovis Chua DE IMUS ,  Neeraj Jagdish AGRAWAL ,  Gunasekaran KANNAN ,  Li LI

IPC: C07K14/55 ,  C07K16/24 ,  A61K38/20 ,  A61P37/00

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US12297292B2

公开(公告)日：2025-05-13

申请号：US15673539

申请日：2017-08-10

Applicant: AMGEN INC. ,  AMGEN RESEARCH (MUNICH) GMBH

Inventor： Shouhua Xiao ,  Zheng Pan ,  Dineli Wickramasinghe ,  Peter Kufer ,  Patrick Hoffmann ,  Tobias Raum ,  Ralf Lutterbüse ,  Elisabeth Nahrwold ,  Claudia Blumel

IPC: C07K16/46 ,  A61K47/60 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: A bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. A nucleic acid comprising a polynucleotide encoding the antibody construct, a vector comprising the nucleic acid comprising the polynucleotide and a host cell transformed or transfected with the nucleic acid comprising the polynucleotide or vector. A process for the production of the antibody construct, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.

公开(公告)号：US20250136653A1

公开(公告)日：2025-05-01

申请号：US18737435

申请日：2024-06-07

Applicant: AMGEN INC.

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: C07K14/50 ,  A61K38/00 ,  A61K38/18 ,  A61K39/00 ,  C07K14/05 ,  C07K16/18

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

公开(公告)号：US20250129172A1

公开(公告)日：2025-04-24

申请号：US18904787

申请日：2024-10-02

Applicant: AMGEN INC.

Inventor： Thomas C. BOONE ,  David W. BRANKOW ,  Colin V. GEGG, JR. ,  Shaw-Fen Sylvia HU ,  Chadwick T. KING ,  Hsieng Sen LU ,  Licheng SHI ,  Cen XU

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C12N5/10 ,  C12N15/00 ,  C12N15/63 ,  G01N33/53

Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.

公开(公告)号：US20250129072A1

公开(公告)日：2025-04-24

申请号：US18987521

申请日：2024-12-19

Applicant: AMGEN INC.

Inventor： Michal ACHMATOWICZ ,  John T. COLYER ,  Michael T. CORBETT ,  Daniel J. GRIFFIN ,  Andrew T. PARSONS ,  Joanna ROBINSON ,  Kyle QUASDORF

IPC: C07D471/04

Abstract: Provided herein is a process for preparing compound A comprising (a) admixing 2-isopropyl-4-methylpyridin-3-amine (Compound B), or a salt thereof, a first base, and a reactive compound comprising phosgene or a phosgene equivalent in an organic solvent to form 3-isocyanato-2-isopropyl-4-methylpyridine (Compound C); (b) admixing Compound C and 2,6-dichloro-5-fluoronicotinamide (Compound D) to form 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Compound E); and (c) admixing Compound E and a second base to form a product mixture comprising Compound A and the second base. Also provided herein is a process for synthesizing AMG 510 comprising using Compound A prepared according to the disclosed processes

公开(公告)号：US20250129050A1

公开(公告)日：2025-04-24

申请号：US18832887

申请日：2023-01-26

Applicant: Amgen Inc.

Inventor： Sebastien CAILLE ,  Daniel Gerard GREENE ,  Michael Thomas CORBETT ,  Carolyn WEI

IPC: C07D401/14 ,  C07D221/20 ,  C07F3/00

Abstract: The present invention relates to improved preparation of a KIF18A inhibitor having the chemical structure Compound (1), or a salt thereof Compound (la); wherein HA is as defined herein; and key intermediates thereof, i.e., Compound (2a), Compound (3a), Compound (5) or a salt thereof, and Compound (6a) or a hydrate thereof, of the formulae: Compound (2a); Compound (3a); Compound (5) or a salt thereof; and Compound (6a) or a hydrate thereof, preferably Compound (6a-1). The present invention further relates to solid form of Compound (6a), preferably the crystalline hydrate form of Compound (6a-1).

公开(公告)号：USD1071160S1

公开(公告)日：2025-04-15

申请号：US29887155

申请日：2023-03-17

Applicant: AMGEN INC.

Designer： Matias Melander ,  Bjarke Lykke Ludvig Svendsen ,  Christian Plambech ,  Michael Sorensen ,  Dylan Bourelle

公开(公告)号：US20250115622A1

公开(公告)日：2025-04-10

申请号：US18730357

申请日：2023-02-03

Applicant: AMGEN INC.

Inventor： Ron C. Kelly ,  Mary Chaves ,  Jing Teng ,  Stephan Parent ,  Markian Stec ,  Van Luu ,  Robert P. Farrell ,  James E. Huckle ,  Michal Achmatowicz ,  Tian Wu ,  Darren Leonard Reid ,  Lingyun Xiao

IPC: C07D519/00 ,  A61K31/553

Abstract: Disclosed herein are crystalline forms of (4S,7aR,9aR,10R,11E,14S,15R)-6′-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3′,4′,7a,8,9,9a,10,13,14,15-decahydro-2′H,3H,5H-spiro[1,19-etheno-1616-cyclobuta[i] [1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-4,1′-naphthalene]-16,16,18(7H,17H)-trione (AMG 397): (AMG 397), hydrates, and solvates thereof. Also disclosed are methods of making the crystalline forms, and methods of treating diseases and disorders with the crystalline forms.

公开(公告)号：US20250108121A1

公开(公告)日：2025-04-03

申请号：US18708513

申请日：2022-11-08

Applicant: AMGEN INC.

Inventor： Jonathan DIEP

IPC: A61K47/68 ,  C07K14/605 ,  C07K16/28

Abstract: The present invention relates to mammalian cells modified to provide for reduced cleavage of peptides that will be conjugated to polypeptides expressed by the cells. In particular, the invention relates to a method of producing an antibody peptide conjugate, the method comprising: a) expressing the antibody in a mammalian cell wherein the mammalian cell is a cathepsin D knock out cell, and wherein the antibody comprises a cysteine or non-canonical amino acid amino acid substitution at one or more conjugation site(s); b) purifying the antibody; and c) conjugating a peptide to the antibody at the conjugation site(s).

公开(公告)号：US12258411B2

公开(公告)日：2025-03-25

申请号：US17831398

申请日：2022-06-02

Applicant: AMGEN INC. ,  AMGEN RESEARCH (MUNICH) GmbH

Inventor： Nathan William Pierce ,  Agnieszka Kielczewska ,  Wentao Chen ,  Olivier Nolan-Stevaux ,  Darren L. Bates ,  Lisa Winkel ,  Christoph Dahlhoff ,  Tobias Raum ,  Claudia Bluemel ,  Jonas Karl-Josef Honer

IPC: C07K16/28 ,  A61K39/00

Abstract: The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.